Despite the important advances made in the analytical analysis of Ab biomarkers, the challenges now are the improvement of methods in terms of sensitivity and specificity, reliability, reproducibility, ease of performance and cost effectiveness, so that they can be applied in routine clinical practice for the diagnosis of AD, in particular in blood samples, and in the early phase of the disease where future therapies are expected to be more effective